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Background: The prognosis for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the inferior vena
cava (IVC) or right atrium (RA) is poor, and there is no established effective treatment for this condition. Thus study
aimed to evaluate the efficacy of surgical resection and prognosis after surgery for such cases.
Methods: Between January 1990 and December 2012, 891 patients underwent hepatectomy for HCC at our
institution. Of these, 13 patients (1.5%) diagnosed with advanced HCC with tumor thrombi in the IVC or RA
underwent hepatectomy and thrombectomy. Data detailing the surgical outcome were evaluated and recurrence-
free and overall survival rates were calculated using the Kaplan-Meier method.
Results: Seven patients had an IVC thrombus and six had an RA thrombus. Extra-hepatic metastasis was diagnosed
in 8 of 13 patients. Surgical procedures included three extended right lobectomies, three extended left
lobectomies, five right lobectomies, and two sectionectomies. Right adrenal gland metastases were excised
simultaneously in two patients. All IVC thrombi were removed under hepatic vascular exclusion and all RA thrombi
were removed under cardiopulmonary bypass (CPB). Four patients (30.8%) experienced controllable postoperative
complications, and there was no surgical mortality. The mean postoperative hospital stay for patients with IVC and
RA thrombi was 23.6 ± 12.5 days and 21.2 ± 4.6 days, respectively. Curative resection was performed in 5 of 13
cases. The 1- and 3-year overall survival rates were 50.4%, and 21.0%, respectively, and the median survival duration
was 15.3 months. The 1- and 3-year overall survival rates for patients who underwent curative surgical resection
were 80.0% and 30.0%, respectively, with a median survival duration of 30.8 months. All patients who underwent
curative resection developed postoperative recurrences, with a median recurrence-free survival duration of 3.8
months. The 1-year survival rate for patients who underwent noncurative surgery and had residual tumors was
29.2%, with a median survival duration of 10.5 months.
Conclusions: Aggressive surgical resection for HCC with tumor thrombi in the IVC or RA can be performed safely
and may improve the prognoses of these patients. However, early recurrence and treatment for recurrent or
metastatic tumors remain unresolved issues.
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Hepatocellular carcinoma (HCC) is a highly malignant
tumor with a propensity for invading intrahepatic blood
vessels such as the portal vein (PV) or hepatic vein in ad-
vanced stages [1]. Further extension of tumor thrombi from
any of the three main hepatic veins or the right inferior
hepatic vein can give rise to thrombi in the inferior vena
cava (IVC) or right atrium (RA) [1-3]. Commonly, the
prognosis of HCC patients presenting with IVC or RA
thrombosis is extremely poor [4-6], and there is no
established management for such cases [4,5,7-17]. Surgical
removal of IVC and RA thrombi combined with hepatec-
tomy is the only radical treatment to decrease the risk of
systemic metastasis and sudden death due to pulmonary
embolism or occlusion of the tricuspid valve with a tumor
thrombus [18-20]. However, aggressive surgical resection is
not common because the surgical approach to IVC and RA
thrombi is considered complicated and hazardous and is
applicable only in limited cases with good hepatic reserve
[4,6,9,16,17]. Therefore, the efficacy of surgical treatment
for HCC with IVC or RA thrombi remains unclear. In this
study, we retrospectively investigated the surgical outcomes
and prognoses of patients who underwent surgery for HCC
with IVC or RA tumor thrombi in a single institution to
clarify the safety and efficacy of surgical resection.
Methods
Patients and diagnoses
Between January 1990 and December 2012, 891 patients
underwent hepatectomy for HCC at the Department of
Gastroenterological Surgery, Hokkaido University, Japan.
The diagnosis of HCC was determined by enhanced com-
puted tomography (CT) and magnetic resonance imaging
(MRI). IVC or RA thrombi were evaluated by CT (Figure 1).
Among those studied, 13 patients (1.5%) diagnosed with
advanced HCC and tumor thrombi in the IVC or RA
underwent hepatectomy. This study was approved by the
Institutional Review Board of the Hokkaido University
School of Advanced Medicine.
The mean age at diagnosis was 63.4 years. The most
common cause of HCC was hepatitis B virus (HBV) in-
fection (53.8%), followed by hepatitis C virus (HCV) in-
fection (15.4%). A total of 12 (92.3%) patients were male,
and according to the Child-Pugh classification, all cases
had Child-Pugh class-A disease. Six (46.2%) patients had
a single tumor and seven (53.8%) had multiple tumors.
The mean main tumor size was 11.8 cm, with nine tu-
mors (69.2%) located in the right lobe and four (30.8%)
in the left lobe. Extra-hepatic metastases were detected
in eight of thirteen (61.5%) patients (five with lung, two
with right adrenal gland and one with mediastinal lymph
node metastases). Seven (53.8%) patients had an IVC
thrombus and five (46.2%) had an RA thrombus
(Table 1).The tumor thrombus arose from the right hepatic vein
in four patients (30.8%), middle hepatic vein in three
(23.1%), left hepatic vein in one (7.7%), inferior right
hepatic vein in two (15.4%), right hepatic vein combined
with the middle hepatic vein in one (7.7%), and right
hepatic vein combined with the inferior right hepatic
vein in one (7.7%). In one patient with right adrenal
gland metastasis, the tumor thrombus arose from the
right adrenal vein (7.7%). Two patients had a mural
thrombus and eleven had a massive thrombus. The
massive thrombi in 10 patients did not completely oc-
clude the IVC because circinate or arc-like luminal flow
in the IVC around the tumor thrombi was present and
the outflow canals of the intact hepatic veins were
maintained. The tumor thrombus of one patient com-
pletely occluded the IVC inferior to the influx of hepatic
veins accompanied by an aggregating blood thrombus.
The outflow canals of the intact hepatic veins were se-
verely narrowed but not completely occluded. One pa-
tient with a thrombus completely occluding the IVC and
two patients with a massive IVC thrombus suffered pre-
operative renal insufficiency, and two had evident leg
edema (Table 2).
Surgical procedures
A lobectomy was performed for patients with an
indocyanine green retention rate at 15 minutes after injec-
tion (ICG R15) of <15% and total bilirubin levels of <1.5
mg/dl without ascites. Patients with an ICG R15 of 15 to
20% and total bilirubin levels of 1.5 to 2.0 mg/dl were eli-
gible for sectionectomy according to our criteria [21]. The
type of surgical procedure was selected based on
Couinaud’s classification [22] and included three extended
right hepatectomies, three extended left hepatectomies,
five right hepatectomies, and two sectionectomies accom-
panied by thrombectomies. The right adrenal gland was
resected simultaneously in two patients with right adrenal
gland metastases (Table 3).
Hepatic resections were performed with an ultrasonic
dissector using the Pringle maneuver in all cases. All
IVC thrombi were removed under hepatic vascular ex-
clusion (HVE). Before thrombectomy, hepatic transec-
tion was performed and the IVC was clamped below and
above the liver. The IVC thrombus was excised en-bloc
from the incised IVC, with satisfactory visualization of
the intraluminal space under HVE. The IVC incision
was closed by a simple continuous suture without a
patch. All RA thrombi were removed under cardiopul-
monary bypass (CPB). Following a laparotomy, a median
sternotomy was performed to prepare for prompt CPB
in anticipation of an undesirable pulmonary tumor em-
bolism from a dislodged thrombus. Hepatic transection
was then performed. The liver was handled gently, par-
ticularly if the thrombus had a long, thin neck, to
Figure 1 Representative computed tomography findings of hepatocellular carcinoma (HCC) with inferior vena cava (IVC) and right
atrium (RA) thrombi. (a and b) A large HCC lesion in the right lobe (T), with a tumor thrombus arising from the right hepatic vein into the IVC
(arrow). (c and d) HCC in the right lobe (T), with a tumor thrombus arising from the inferior right hepatic vein into the IVC (arrow). (e, f, and g)
HCC in the left lobe (T), with a tumor thrombus arising from the left hepatic vein into the RA (arrow).
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perior vena cava (SVC) and IVC below the liver were
clamped and blood flow was bypassed to the ascending
aorta via an oxygenator. The RA was incised and the
thrombus was excised en-bloc under direct vision. In
most cases, the RA was reconstructed by simple sutures,
but in two cases, an invaded RA wall was partially ex-
cised and reconstructed using an artificial graft or peri-
cardial patch. In addition to CPB, one patient with
complete IVC occlusion accompanied by severe obstruc-
tion of intact hepatic outflow and one patient with
tumor thrombi that arose from two major hepatic veins
showed gross hepatic congestion due to outflow block at
surgery. These cases needed extracorporeal bypass from
the portal vein (PV) and IVC to SVC (Table 3). In all
cases, thrombi were intraoperatively monitored bytransesophageal echocardiography. In this study, we de-
fined curative resection as macroscopic complete exci-
sion of the tumors, including metastatic lesions.
Follow up
The median duration of follow up was 11.2 (range, 1.8 to
51.8) months. Hospital death was defined as death occur-
ring within 30 days of the first hospitalization. After
surgery, CT or MRI was performed at 1- to 3-month in-
tervals to determine recurrence. Data on surgical out-
comes, postoperative management, recurrence, treatment
of recurrence, and survival was analyzed for all cases.
Statistical analysis
Survival rates were analyzed by the Kaplan-Meier
method and statistical significance was determined by
Table 1 Characteristics of patients and tumors
Characteristic Value
Total number of patients 13
Age, years
















Inferior vena cava/right atrium 7/6
Preoperative extrahepatic metastases
None/lung/adrenal gland/lymph nodes 5/5/2/1
Status of metastases after surgery
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Cary, NC, USA). Significance was defined as P <0.05.
Results
Surgical outcomes and postoperative complications
With regard to patients with an IVC thrombus, the
mean surgical duration was 349 ± 30 minutes, the me-
dian blood loss was 950 ± 100 ml, and the mean HVE
duration was 8.8 ± 3.1 minutes. Two of seven (28.6%)
patients needed blood transfusions. No patient required
an ICU stay, and the mean postoperative hospital stay
was 23.6 ± 12.5 days. After surgery, one patient experi-
enced biloma and one experienced controllable ascites.
With regard to patients with an RA thrombus, the mean
surgical duration was 608 ± 169 minutes, the median
blood loss was 6540 ± 5404 ml, and the mean CPB dur-
ation was 32.2 ± 18.3 minutes. Five of six (83.3%)
patients needed blood transfusions. The mean posto-
perative ICU stay was 1.7 ± 0.8 days and the mean post-
operative hospital stay was 21.2 ± 4.6 days. After surgery,one patient experienced acute renal failure and one ex-
perienced atrial fibrillation, but these patients recovered
with medical therapy. There was no postoperative mor-
tality. All IVC and RA thrombi were excised completely.
Curative resection was performed in five of thirteen
(38.5%) cases (Table 4).
Postoperative management
Among the five patients (38.5%) who underwent curative
resection, adjuvant systemic chemotherapy was adminis-
tered to four. The chemotherapeutic agents used in
combination included intravenous 5-fluorouracil (5-FU;
500 mg weekly) and peroral tegafur uracil (UFT; 300 mg
daily) in three patients and peroral UFT (300 mg daily)
in one. One patient was followed up without adjuvant
chemotherapy.
Tumors remained after surgery in eight (61.5%) pa-
tients, including lung metastases in four, intrahepatic
metastases in two, both intrahepatic and lung metastases
in one, and mediastinal lymph node metastases in one.
Residual lung metastases were treated with oral adminis-
tration of UFT in two patients, 5-FU + UFT in one pa-
tient, and oral administration of tegafur gimeracil
oteracil potassium (S-1) followed by surgical resection in
one patient. Unresectable intrahepatic metastases were
treated with UFT in two patients and transarterial
chemoembolization (TACE) in one patient. A patient
with residual mediastinal lymph node metastasis re-
ceived radiation after surgery.
Recurrence and survival
All five patients who underwent curative resection experi-
enced postoperative recurrences. Intrahepatic recurrences
appeared in all five patients, lung metastases in four, intra-
IVC metastases in one, and left adrenal gland metastases
in one patient. The median recurrence-free survival dur-
ation of the patients who underwent curative resection
was 3.8 months. Intrahepatic recurrences were treated
with TACE in three patients, radiofrequency ablation
(RFA) in two, and radiotherapy in one patient. Lung me-
tastases were treated with systemic chemotherapy in three
patients (5-FU + UFT in two, cisplatin (CDDP) + S-1
followed by oral administration of sorafenib in one pa-
tient), and surgical resection in one patient. Left adrenal
gland metastases were surgically excised.
Among the eight patients who underwent noncurative
resection, four of five with lung metastases exhibited pro-
gression of the metastases. In one patient, lung metastasis
was resected but recurred after resection. Intrahepatic re-
sidual tumors in three patients progressed after surgery;
however, mediastinal lymph node metastases treated by ir-
radiation remained unchanged. Among these eight pa-
tients, seven experienced further dissemination of the
tumor to new locations, including the lung in three, lymph
Table 2 Characteristics of tumor thrombi
Patients age/sex Involved veins Extent of thrombus Advance of thrombus Symptoms associated with the thrombus
68/M RHV Massive RA Renal insufficiency/lower limb edema
57/M RAdV Massive IVC Renal insufficiency
70/M RHV IVC occlusive RA Renal insufficiency/lower limb edema
86/F RHV Massive IVC (−)
68/M IRHV Mural IVC (−)
66/M RHV Massive RA (−)
37/M IRHV Massive IVC (−)
56/M RHV/IRHV Massive IVC (−)
51/M LHV Massive RA (−)
72/M MHV Mural IVC (−)
59/M LHV/MHV Massive RA (−)
69/M MHV Massive IVC (−)
65/M MHV Massive RA (−)
M male, RHV Right hepatic vein, RAdV right adrenal vein, IRHV inferior right hepatic vein, LHV left hepatic vein, MHV, middle hepatic vein, IVC inferior vena cava, RA
right atrium. (−), no symptom.
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in 1 (Tables 1 and 5).
The 1-, and 3-year overall survival rates for all 13 pa-
tients were 50.4% and 21.0%, respectively, and the over-
all median survival duration was 15.3 months. The cause
of postoperative death in all patients was cancer, which
remained at surgery or recurred after surgery (Table 5).
The overall survival rate for patients with IVC thrombi
was 57.1% at 1 year and 42.9% at 3 years, with median





(n = 7) (n = 6)
Surgical procedure
Extended right hepatectomy 1 1
Extended right hepatectomy +
right adrenectomy
0 1
Right hepatectomy 3 1
Right hepatectomy + right
adrenectomy
1 0
Extended left hepatectomy 1 2
Sectionectomy 1 1
Inflow vascular control
Hepatic vascular exclusion 7 0
Cardiopulmonary bypass 0 4
CPB + portal vein/inferior vena
cava to superior vena cava bypass
0 2
Vascular wall reconstruction
Simple closure 7 4
Patch reconstruction 0 2survival rate for patients with RA thrombi was 40.0%,
with median survival duration of 11.2 months. There
was no significant difference between the IVC thrombi
and RA thrombi groups (Figure 2a). The survival rates
for patients who underwent curative surgical resection
were 80.0% at 1 year and 30.0% at 3 years, with a median
survival time of 30.8 months. Meanwhile, the 1-year sur-
vival rate for patients who underwent noncurative sur-
gery and had residual tumors was 29.2%, with a median
survival time of 10.5 months (Figure 2b). The longest
survival time was 51.8 months for patients who under-
went complete resection and 29.3 months (to date) for
those who underwent incomplete resection, and they are
still alive (Table 5).
Discussion
IVC and RA tumor thrombi arising from HCC are un-
common and are found in approximately 3 to 4% of
HCC patients [2,23]. It is recognized that tumor invasion
into intrahepatic vessels, such as the portal or hepatic
veins, is an important prognostic factor for patients with
HCC [24]. In particular, the prognosis of patients pre-
senting with ICV or RA thrombi is extremely dismal [6].
Although surgical treatments as well as nonsurgical
treatments such as TACE, radiotherapy, and chemother-
apy are reported, optimal therapeutic management of
IVC and RA thrombi has not been established because
of the paucity of data [5,7,8,10-16]. Some reports demon-
strate the potential benefit of surgical resection, but there
are few reports that consolidate the efficacy of a surgical
approach because IVC and RA thrombi are rare and be-
cause these reports are typically case reports or descrip-
tions of a small number of patients [4,9,16,17,20,25,26].
Reports detailing the surgical treatment of RA thrombi
Table 4 Surgical outcomes
Inferior vena cava thrombus Right atrium thrombus
Surgical duration (minutes)
Mean ± SD (range) 349 ± 30 (288 to 377) 608 ± 169 (449 to 911)
Blood loss (ml)




Mean ± SD (range) 8.8 ± 3.1 (8 to 13) -
CPB time (minutes)




Mean ± SD (range) - 1.7 ± 0.8 (0–2)
Hospital stay (days)
Mean ± SD (range) 23.6 ± 12.5 (14 to 48) 21.2 ± 4.6 (16 to 28)
Complications
Yes/no 2 (ascites, 1; biloma, 1)/5 2 (ARF, 1; Af, 1)/4
HVE hepatic vascular exclusion, CPB cardiopulmonary bypass, ARF acute renal failure, Af atrial fibrillation.
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report on the surgical treatment of IVC and RA thrombi,
including six cases of RA thrombectomy, from a single
institute.
It is generally assumed that liver resection combined
with IVC or RA thrombectomy is a challenging and haz-
ardous procedure that involves a high surgical risk.
According to past reports, hepatectomy together with IVC







68/M RA (−) (−)
57/M IVC (−) (−)
70/M RA (+) (−)
86/F IVC (−) (−)
68/M IVC (−) (−)
66/M RA (−) (+) (lung)
37/M IVC (−) (+) (lung)
56/M IVC (−) (+) (lung)
51/M RA (−) (+) (lung)
72/M IVC (+) (+) (lung)
59/M RA (−) (−)
69/M IVC (−) (+) (LN)
65/M RA (+) (−)
Ad adrenal gland, IVC inferior vena cava, LN lymph node.of 40% and a high mortality of 15% [4,15]. However, recent
surgical innovations such as the inflow vascular control
method together with refinement of the assessment of pre-
operative hepatic reserve have improved the safety of hepa-
tectomy and thrombectomy procedures [26,27]. This
progress has encouraged us to accept the challenge of ag-
gressive surgical treatment for IVC and RA thrombi.
Effective control of intraoperative hemorrhage plays a
crucial role in hepatectomy procedures combined withMetastatic recurrence Outcome (cause of death)
Hepatic Distant
(+) (+) (lung, Ad) 30.8 months; dead (cancer)
(+) (−) 10.1 months; dead (cancer)
(+) (lung) 9.1 months; dead (cancer)
(+) (+) (lung, IVC) 15.3 months; dead (cancer)
(+) (+) (lung, LN) 51.8 months; alive
(+) (+) (LN) 11.2 months; dead (cancer)
(−) (+) (Ad, LN, Brain) 10.5 months; dead (cancer)
(−) (−) 29.3 months; alive
(+) (+) (Brain) 8.5 months; dead (cancer)
(+) (LN) 1.9 months; dead (cancer)
(+) (+) (lung) 16.5 months; alive
(+) (+) (lung, IVC) 16.0 months; alive
(+) (lung) 7.6 months; alive
Figure 2 Survival curve for patients with hepatocellular
carcinoma (HCC) and inferior vena cava (IVC) and right atrium
(RA) thrombi. (a) Overall survival curve for all patients (n = 13),
patients with IVC thrombus, and patients with RA thrombus.
P = 0.6056 by log-rank test, IVC thrombus versus RA thrombus. (b)
Overall survival curve for patients who underwent curative surgical
resection and noncurative resection. P = 0.2103 by log-rank test,
curative resection versus noncurative resection.
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ing is a major predictive factor for operative morbidity
and mortality [21]. In this study, hepatic parenchymal
transection was routinely performed prior to thrombec-
tomy using the Pringle maneuver. IVC occlusion at the
suprahepatic portion with bulky tumor thrombi evokes
Budd-Chiari syndrome and massive hepatic congestion
[28]. In this study, we observed hepatic congestion in
patients with outflow obstruction of spared hepatic veins
by a massive tumor thrombus. Furthermore, occlusion
of two of three major hepatic veins by venous invasion
induced hepatic congestion, even though the spared
hepatic vein was not obstructed. We used extracorporeal
bypass from the PV and IVC to SVC to decompress the
liver parenchyma and decrease bleeding during hepatic
transection in two patients with an RA thrombus [29].
We performed IVC thrombectomy under a favorablefield with good bleeding control by HVE. The duration
of HVE, which could trigger hemodynamic deterioration,
was short enough. Although CPB was mandatory for RA
thrombectomy and was accompanied with a larger
amount of blood loss and a higher rate of blood transfu-
sion, patients with RA thrombi required minimal ICU
stays and shorter postoperative hospitalization. These
procedures contributed to a low incidence of postopera-
tive non-serious complications that were medically man-
ageable. Furthermore, we did not observe any operative
mortality in this study. Therefore, hepatectomy with
IVC or RA thrombectomy, although technically challen-
ging, can be performed safely with appropriate inflow vas-
cular control for patients with good hepatic reserve.
Because almost all thrombi had capsules and did not ad-
here to the wall of the IVC or RA, they were simply re-
moved by thrombectomy without wall resection. Although
some authors indicate the efficacy of IVC resection, the
benefits are controversial [30]. We experienced two cases
of intra-IVC recurrence after surgery (Table 5); there-
fore, the management of such tumor thrombi should be
reconsidered.
The prognosis of HCC patients with IVC or RA tumor
thrombi is extremely poor. Earlier observations revealed a
median survival duration after diagnosis of 1 to 5 months
for untreated patients [4,15,31]. Although there is no con-
sensus on the therapeutic options for HCC with IVC or
RA thrombi, nonsurgical treatments such as TACE, as
well as radiotherapy and chemotherapy, have been
attempted. Previous reports concerning the therapeutic
benefits of TACE with or without radiotherapy revealed
insufficient results, with a median survival duration of 9.2
months (range, 4.2 to 18.4 months) [4,8,11-13,32]. Cur-
rently, the outcome of systemic chemotherapy for HCC
has been disappointing, although sorafenib, which is the
only effective agent against HCC, demonstrated a slightly
better prognosis of 10.7 months in patients with unre-
sectable HCC [33]. Some case reports have suggested the
efficacy of surgical resection, and, recently, Wang et al.
reported the significant superiority of a surgical approach
to HCC with IVC or RA thrombi, with a median survival
duration of 19 months, compared with TACE with or
without chemoradiotherapy or no treatment [4,6,9,16,
17,20,26,27,34]. This study included 56 patients, of whom
25 underwent surgery, although 7 had an RA thrombus
and only 3 underwent surgical resection for the same [4].
Therefore, the therapeutic benefit of surgical resection for
HCC with an RA thrombus remains unclear. In the
present study, the median overall survival duration of pa-
tients with an IVC or RA thrombus was comparable at
15.3 months and 11.2 months, respectively (Figure 2a).
This finding indicates the equivalent therapeutic efficacy
of surgical resection for RA or IVC thrombi. These results
for patient survival are slightly worse than those of the
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who underwent non-curative resection. The median sur-
vival duration of patients who underwent curative resec-
tion was 30.8 months, which is longer than that in the
previous report [4] (Figure 2b). This result also surpasses
nonsurgical treatment with sorafenib, which resulted in
median survival duration of 8.1 months in patients with
macrovascular invasion [35].
All patients who underwent curative surgical resection
experienced local recurrence or distant metastasis in the
early postoperative phase, despite the fact that almost all
patients received adjuvant chemotherapy (Table 5). It has
been recognized that the poor prognosis of HCC with
tumor thrombi in the IVC or RA is strongly related to a
high incidence of postoperative recurrence at a relatively
early stage, even after curative surgery. In this study, most
patients who underwent curative resection developed
postoperative lung metastases and intrahepatic recurrence
at an equal rate. Preoperative or intraoperative dissemin-
ation of tumor cells to the lung can contribute to pos-
toperative metastatic recurrence. To prevent potential
intraoperative dissemination by intraoperative handling,
some authors indicated the benefit of separated thrombec-
tomy before hepatic transection [36]. However, it could be
technically difficult to remove a thrombus en-bloc without
up-front hepatic transection; therefore, further improve-
ments in surgical techniques are required. To date, there
is no clear modality established for preventing HCC recur-
rence [4,16,37]. The efficacy of preoperative radiotherapy
is indicated for PV tumor thrombi [38]; however, the
benefit for IVC or RA thrombi is unclear and there re-
mains a risk of thrombi dislodgment during radiation. In
this study, locally recurrent tumors were controlled by
TACE or RFA and distant metastatic tumors were treated
by chemotherapy with or without radiotherapy or surgical
excision if resectable. These vigorous repetitive treat-
ments contribute to improvement in survival, even after
recurrence.
Surgical resection is commonly contraindicated for pa-
tients with unresectable metastatic tumors because in-
complete resection is a crucial factor for poor prognosis
[6]. However, hepatic lesions, but not distant metastasis,
are the major factors influencing poor prognosis for
death in the early postoperative phase [39]. On the basis
of the fact that the survival duration of patients with
IVC or RA thrombi is extremely short with nonsurgical
treatment, distant metastasis itself should not be consid-
ered a contraindication for surgery. In this study, eight
patients underwent noncurative surgery, and the median
survival duration of 10.5 months was relatively better
than that for patients who underwent nonsurgical treat-
ment or no treatment in previous studies, including pa-
tients who received sorafenib, which is the only highly
evidenced agent for advanced HCC treatment andresults in median survival duration of 8.9 months in
patients with extrahepatic metastases [4,8,11-13,15,
30-32,35]. Recent reports indicate the efficacy of aggres-
sive treatment for HCC metastases, including those to the
lung, adrenal gland, and lymph nodes, by surgery or radio-
therapy [40-42]. In this study, a patient with lung metasta-
ses at primary surgery underwent resection of the
metastases and survived for 29.3 months. These findings in-
dicate that reductive surgical resection can be justified in
patients with IVC or RA thrombi accompanied by distant
metastases or unresectable intrahepatic metastases. Control
of the life-threatening progression of intrahepatic HCC and
prevention of unexpected death by pulmonary embolism
would give these patients a chance to undergo multidiscip-
linary treatments for improving survival. Therefore, if
intrahepatic HCC and IVC or RA thrombi can be totally or
partially resected, surgical resection may be beneficial.
The limitations of this study include its retrospective
design, its single-center design, the small sample size,
and patient heterogeneity. Because IVC and RA thrombi
associated with HCC are rare, a multicenter prospective
study with a large patients sample is necessary to defini-
tively establish the benefits of surgical management.
Conclusions
In conclusion, surgical resection of HCC with IVC or RA
thrombosis can be performed safely with appropriate in-
flow vascular control in patients with good hepatic re-
serve. We suggest that aggressive surgical resection may
be more beneficial than existing therapeutic modalities;
however, early recurrence and treatment of recurrent or
metastatic tumors remain unresolved issues. Further stud-
ies on adjuvant therapies and establishment of therapeutic
strategies for recurrent and metastatic tumors are import-
ant challenges to improve survival.
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